TrialEuropean urology2024

Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.

Nobuaki Matsubara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.